Novartis shares jump as drugmaker boosts outlook
By Steve Goldstein
Novartis shares rallied on Tuesday as the Swiss drugmaker raised its outlook for the year after seeing strong demand for heart and psoriasis drugs.
Novartis said it's now expecting sales growth in the high single to low double-digits for 2024, up from mid single digits, and core operating profit growth in the low double-digit to mid-teens, from high single digits.
Its first-quarter profit rose 25% to $2.69 billion as sales rose 10% to $11.83 billion. Its core earnings per share rose 17% to $1.80. Analysts polled by Visible Alpha expected a core EPS of $1.67 on sales of $11.38 billion.
Novartis shares (CH:NOVN) (NVS) rose 5% in Swiss trade, bringing its year-to-date gains to 8%.
During the quarter, sales of its heart drug Entresto rose 36% at constant currencies to $1.88 billion, and sales of arthritis drug Cosentyx rose 25% to $1.33 billion. Its top 20 brands saw sales growth of 16%, or 18% at constant currencies.
The company said it's going to nominate Giovanni Caforio, the former CEO of Bristol-Myers Squibb and until last its month its executive chairman, to be chair when Joerg Reinhardt retires next year.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-23-24 0348ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations